Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective
Abstract
Authors
M. Charokopou H. Vioix B.G. Verheggen S. Dillon D. Franks